Natera Q2 FY25 earnings call NTRA

Natera reported record Signatera volumes in Q2 FY25, with 189,000 oncology tests processed, marking a sequential increase of nearly 20,000 units. This growth was significantly driven by new patient starts, which doubled the previous quarterly record. While colorectal cancer, breast cancer, and IO monitoring remain strong drivers, the company is observing broader adoption across various tumor types, leading to a large revenue opportunity and efforts to secure Medicare reimbursement for these non-covered histologies.

Revenue grew 32% year-over-year to $547 million, or 34% excluding true-up^📎s. Gross margin improved to 63.4% from 59% last year, with ex-true-up^📎 gross margins consistent sequentially despite increased exome volumes. The company highlighted four vectors for margin expansion: continued revenue cycle operations improvements, expanded product coverage (including Signatera), COGS reductions, and AI-driven efficiencies. Day Sales Outstanding (DSOs) reached a record low of 57 days, reflecting improved cash conversion.

Despite raising revenue guidance, Natera is holding its operating expense guidance flat, demonstrating scale in the business. Incremental investments in 2025 are directed towards gaining reimbursement for uncovered services, major clinical trials, new product launches, and expanding the commercial footprint, particularly in oncology. These investments are expected to drive revenue and volume growth in 2026 and beyond, with a 'slingshot effect' where current expenses precede future productivity.

Natera launched Fetal Focus, a new NIPT for inherited conditions, leveraging its proprietary SNP-based method. This test addresses an unmet clinical need by assessing a baby's risk of inheriting genetic conditions from a maternal blood sample when the father is unavailable for testing. Backed by data from the EXPAND trial, which demonstrated 91% sensitivity for affected pregnancies, Fetal Focus reinforces Natera's leadership in women's reproductive health.

The PEDAL study, published in the American Journal of Transplantation, demonstrated that serial monitoring with Prospera can inform patient management during treatment for acute kidney transplant rejection. Patients with persistently high donor DNA levels had 97.5% negative outcomes, while those with dropping levels were 60x more likely to experience positive long-term outcomes. This new use case complements existing utility in surveillance and aligns with recent positive draft LCD updates from Medicare.

Significant clinical data was presented for Signatera, including interim results from the DARE trial in early-stage breast cancer, showing excellent test sensitivity and viability of a 'treatment on molecular recurrence' (TOMR) strategy. New data from the ISPY-2 trial and the launch of the TEODOR trial further solidify Signatera's role in breast cancer. Additionally, strong peer-reviewed publications in gastroesophageal (PLAGAST study) and liver cancers (HCC study) highlight Signatera's potential to improve patient management and outcomes in these deadly diseases.

Natera continues to advance its ECD program with over 3,500 patients consented for the PROCEED-CRC study, a prospective average-risk colonoscopy-matched trial. A significant readout from PROCEED, assessing assay performance in advanced adenoma and normal controls, is expected late this fall. The FDA-enabling FIND study has also commenced enrollment and is on track for an FDA submission in 2027, with investments for this program already integrated into operating expenses.

Natera is deploying AI across the company to scale operations, improve user experience, and drive scientific innovation. The AI-based discovery platform, built on a multimodal longitudinal oncology dataset of over 250,000 patients, powers digital twins for treatment optimization and virtual clinical trials. New algorithms like NeoPredict and NeoSelect predict immunotherapy response and identify neoantigenic mutations, with NeoSelect outperforming 25 established models in benchmarking. These AI initiatives are expected to generate significant savings and new commercial opportunities.